Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Income towards Parent Company: 2022-2024

Historic Income towards Parent Company for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$60.9 million.

  • Orchestra BioMed Holdings' Income towards Parent Company fell 35.02% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 33.72%. This contributed to the annual value of -$60.9 million for FY2024, which is 27.88% down from last year.
  • As of FY2024, Orchestra BioMed Holdings' Income towards Parent Company stood at -$60.9 million, which was down 27.88% from -$47.7 million recorded in FY2023.
  • Orchestra BioMed Holdings' Income towards Parent Company's 5-year high stood at -$32.7 million during FY2022, with a 5-year trough of -$60.9 million in FY2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$47.7 million (2023), whereas its average is -$47.1 million.
  • Data for Orchestra BioMed Holdings' Income towards Parent Company shows a maximum YoY tumbled of 45.93% (in 2023) over the last 5 years.
  • Orchestra BioMed Holdings' Income towards Parent Company (Yearly) stood at -$32.7 million in 2022, then crashed by 45.93% to -$47.7 million in 2023, then decreased by 27.88% to -$60.9 million in 2024.